For people living with diabetes and using an insulin pen, questions abound throughout the day: What is my glucose level? When was my last dose of insulin? Should I take another now? But the question that stands above all: Why can’t there be a better way? Abbott and Novo Nordisk have an answer: There can be. And soon, there will be. By combining the technology behind our FreeStyle Libre system — which is the fastest growing continuous glucose monitoring system (CGM) on the market with more than 1.3 million users1 — with Novo Nordisk’s connected insulin pens, managing your diabetes is going to get a whole lot easier. 'Lack of reliable information is a cause of huge frustration for many people with diabetes and their doctors,' said Anders Dyhr Toft, corporate vice president, Commercial Innovation, Novo Nordisk. 'With partners like Abbott, our connected pens will give healthcare professionals a better understanding of a patient's individual diabetes management and can help people with diabetes feel more confident in their treatment.'